Breaking the Clot: Can eNO Protect the ECMO Circuit? — Summary

1. Introduction

  • Focus: Relationship between coagulation, inflammation, and the potential of nitric oxide (NO) in ECMO sweep gas to reduce both.

  • Context: ECMO circuit safety, anticoagulation evolution, and the role of team-based care.

2. Historical Background

  • Pioneers:

    • Early ECMO developments by Ted Cobo and Warren Zapol.

    • First successful ECMO case (1971) demonstrated importance of managing anticoagulation and bleeding.

  • Evolution of Oxygenators:

    • Transition from solid silicon to polymethyl pentene (PMP) membranes enabled coating and reduced surface area.

  • Anticoagulants:

    • Shift from unfractionated heparin to low molecular weight heparin and direct thrombin inhibitors (bivalirudin).

    • Persistent clot formation despite anticoagulation highlights ongoing challenges.

3. Nitric Oxide and Platelet Interaction

  • Role of NO:

    • Naturally reduces platelet activation at vascular endothelium.

    • Easily administered through ECMO sweep gas.

  • Clinical Interest:

    • NO may mitigate inflammation and clotting within ECMO circuits.

    • Early clinical experiences demonstrate safety, though efficacy remains uncertain.

4. Research and Trials

  • Retrospective Studies:

    • Early pediatric experience with NO in sweep gas showed safety but no clear efficacy.

  • NECTAR Trial:

    • Randomized, single-center study using 20 ppm NO.

    • Demonstrated feasibility and safety but limited by small sample size and heterogeneous patient population.

    • No differences in survival or methemoglobinemia; reduced blood product usage noted.

  • Ongoing Questions:

    • Optimal dosing and delivery method remain undefined.

    • Potential differential effect with direct thrombin inhibitors versus heparin.

5. Case Example — “Aubrey”

  • Clinical Story:

    • Infant with RSV pneumonia and MRSA infection managed on prolonged ECMO (234 days).

    • Supported with bivalirudin and 20 ppm NO in sweep gas.

    • Oxygenator remained clot-free after five months of use.

    • Full recovery, decannulation, and discharge after 301 hospital days.

  • Implications:

    • NO may prolong membrane life and exert anti-inflammatory effects aiding recovery.

6. Conclusion

  • Key Points:

    • eNO in sweep gas is safe and feasible in ECMO.

    • Evidence for efficacy remains limited but promising.

    • May reduce clot formation and inflammation, extending membrane life.

    • Further studies needed to determine optimal dosing, patient selection, and mechanisms.

 

PreviousNext